Amgen Is The First Biologic To Publish Data Showing Safety And Sustained Efficacy For Up To Nine Years In Patients With Moderate-To-Severe Rheumatoid Arthritis

THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Amgen (NASDAQ:AMGN) today announced that Enbrel® (etanercept) is the first biologic with published data to show improvements in multiple measures of efficacy that were sustained in rheumatoid arthritis (RA) patients completing up to nine years of therapy. These new data are being presented at the American College of Rheumatology (ACR) Scientific Meeting in Washington, D.C.